Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sonoma Relaunches Prescription Dermatology and Eye Care Products in the US
Details : Acuicyn (hypochlorous acid) is an antimicrobial eyelid and eyelash hygiene solution which removes encrustation and debris, to help manage red, inflamed, itchy eyes.
Product Name : Acuicyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Reports Positive RLF-TD011 Results for Epidermolysis Bullosa Clinical Trial
Details : RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology, being developed for the treatment of epidermolysis bullosa.
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : SWK Holdings Corporation
Deal Size : $11.0 million
Deal Type : Financing
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Details : The funding will advance company pipeline, including the clinical development of its patent-protected Nexodyn AOS (hypochlorous acid) topical spray, RLF-TD011, for treating epidermolysis bullosa.
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 23, 2024
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : SWK Holdings Corporation
Deal Size : $11.0 million
Deal Type : Financing
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Reports Promising Results For RLF-TD011 in EB Trial
Details : Nexodyn AOS is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO technology. It is being evaluated for the treatment of epidermolysis bullosa.
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : SWK Holdings Corporation
Deal Size : $11.0 million
Deal Type : Financing
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Details : The funding will advance company pipeline, including the clinical development of its patent-protected Nexodyn AOS (hypochlorous acid) topical spray, RLF-TD011, for treating epidermolysis bullosa.
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : SWK Holdings Corporation
Deal Size : $11.0 million
Deal Type : Financing
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Regenacyn Plus (Hypochlorous acid), is an anti-allergic, anti-inflammatory and antipruritic most effective scar gel. It has dual action healing process for infection control, improving new and old keloid and hypertrophic scars and accelerating wound heal...
Product Name : Regenacyn Plus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Daewoong Pharmaceutical will have the exclusive right to market, sell and distribute Primocyn (hypochlorous acid) Skin Solution products, containing Sonoma's Microcyn technology, in South Korea.
Product Name : Primocyn
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 31, 2023
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Daewoong Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Reliefacyn (hypochlorous acid) is antipruritic, anti-inflammatory, and anti-allergic. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic ...
Product Name : Reliefacyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nexodyn® Acid-Oxidizing Solution (AOS) is a Tehclo®-based product proven to restart wound healing and intended for use in the debridement, irrigation, cleansing and moistening of chronic wounds and acute wounds, post-surgical wounds, cuts, abrasions, b...
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nexodyn® Acid-Oxidizing Solution is a Tehclo®-based with three main features: highly pure and stabilized hypochlorous acid, acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential proven to restart wound healing.
Product Name : Nexodyn AOS
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable